Genetic medicine company enGene Holdings Inc. appointed Hussein Sweiti as Chief Medical Officer, effective September 29, 2025. Sweiti, a surgical oncologist and physician-scientist with 15+ years of experience, will lead global clinical development strategy for the company’s lead investigational candidate in NMIBC. Previously, he served as Global Medical Head, Oncology Clinical Development at Johnson & Johnson, overseeing clinical strategy for the bladder cancer portfolio. His appointment marks enGene’s growth stage as it progresses towards potential commercialization. Sweiti’s expertise in clinical practice, oncology research, and regulatory submissions will be key in driving future clinical development programs.

Read more at Nasdaq: EnGene Appoints Hussein Sweiti As Chief Medical Officer